Company intelligence / Profile preview

Trilo Therapeutics

San Francisco, California, USAtrilotherapeutics.com ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

Developing mirror-image cyclic peptides (Trilomers®) that enable targeted delivery of potent chemotherapy drugs for cancer treatment. Their technology aims to overcome limitations of traditional antibody-drug conjugates by using 100% D-amino acids that are resistant to proteases and exhibit low uptake by renal scavenger receptors.

Therapeutic areas: Oncology
Modalities: Mirror-image cyclic peptides (Trilomers®)Peptide-drug conjugates
Industry: Biotech

Drug pipeline

4 assets

Trilomer-HER2 conjugate

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Trilo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trilo Therapeutics.

Explore the full profile